The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Sledge, George W., Toi, Masakazu, Neven, Patrick, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A., Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Lu, Yi, Barriga, Susana, Hurt, Karla, Frenzel, Martin, Johnston, Stephen, Llombart-Cussac, Antonio
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777264/
https://ncbi.nlm.nih.gov/pubmed/31563959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.4782
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars